C3.ai (AI): Director Granted 30,264 Options at $19.16 Exercise Price
C3.ai, Inc. (AI) reported a Form 4 filing showing that director D. Bruce Sewell was granted 30,264 stock options on 10/03/2025 with an exercise price of $19.16 per share.
Rhea-AI Filing Summary
C3.ai, Inc. (AI) reported a Form 4 filing showing that director D. Bruce Sewell was granted 30,264 stock options on 10/03/2025 with an exercise price of $19.16 per share. The options are exercisable through 10/02/2035 and are held directly by the reporting person.
The awards vest on a quarterly schedule starting on the Vesting Commencement Date of 10/03/2025, with 12.5% of the option shares vesting on the last day of each fiscal quarter for two years, subject to the director’s in-person attendance at regularly scheduled board meetings. Missed meetings suspend vesting for the affected quarterly tranche until attendance requirements are later satisfied. The report was signed by an attorney-in-fact on 10/07/2025.
Positive
- 30,264 options granted aligns director incentives with shareholders through equity ownership
- Long-term term (until 10/02/2035) supports retention and focus on multi-year performance
- Direct ownership simplifies alignment—options are held directly by the reporting person
Negative
- Vesting suspended for missed board meetings, creating execution risk if attendance lapses
- Potential dilution if all 30,264 options are exercised over the ten-year term
Insights
Director option grant ties compensation to long-term share performance while enforcing board attendance.
The grant of 30,264 options at an exercise price of $19.16 vests across quarterly tranches beginning 10/03/2025, encouraging continued service through the two-year vesting window ending after the second anniversary. The direct ownership form signals straightforward alignment between the director and shareholders.
Vesting is explicitly conditioned on in-person attendance at regularly scheduled board meetings; missed meetings suspend vesting until attendance requirements are met. Monitor quarterly vesting results and any future filings that show exercised options or changes in beneficial ownership.
The grant is a routine long-term incentive but creates a known dilution cap of 30,264 shares if fully exercised.
With an exercise price of $19.16 and a ten-year term to 10/02/2035, the award is a standard equity-based retention tool that vests 12.5% per quarter for two years. The terms tie realized value to future share price appreciation above the exercise price.
Near-term investor items to watch include any Form 4 updates showing exercises or sales and the company's overall outstanding share count to quantify dilution from full exercise of these options within the stated ten-year term.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 30,264 | $0.00 | $0.00 |
Footnotes (1)
- F1. Provided the Reporting Person remains a director of the Company and attends in person the regularly scheduled meeting of the Board during each fiscal quarter following October 3, 2025 (the "Vesting Commencement Date") until the two-year anniversary date, 12.5% of the shares subject to the option shall vest on the last day of each such fiscal quarter (the "Quarterly Shares") during the term of the option, provided, however, if the Reporting Person fails to attend any such regularly scheduled meeting, then vesting for the Quarterly Shares shall not occur and will be suspended (any such suspended Quarterly Shares being referred to collectively as the "Suspended Shares"). For any Suspended Shares, such shares shall vest only following the second anniversary of the Vesting Commencement Date, if the Reporting Person satisfies the attendance requirements in subsequent periods.
FAQ
What did C3.ai (AI) disclose in the Form 4 filed on 10/07/2025?
How do the options for the AI director vest?
Are the options held directly or indirectly for the AI director?
What is the exercise price and expiration for the AI director options?
Will missed board meetings affect vesting of the AI director's options?
AI-generated analysis. How Rhea-AI works. Not financial advice.